- The Myeloma Beacon - https://myelomabeacon.org -
Xgeva (denosumab, AMG162)
By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled
| Brand Name: | Xgeva (also marketed as Prolia) |
| Generic Name: | denosumab |
| Code Name: | AMG162 |
| Company: | Amgen |
| FDA Clinical Phase: | 2 & 3 |
Description:
Prolia is a human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma, and giant cell tumor of bone. Prolia is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Prolia therefore mimics the endogenous effects of osteoprotegerin.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Official website for denosumab: http://www.amgen.com/science/pipe_denosumab.html [2]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2008/10/15/denosumab/
URLs in this post:
[1] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=denosumab&cond=myeloma
[2] http://www.amgen.com/science/pipe_denosumab.html: http://www.amgen.com/science/pipe_denosumab.html
[3] http://en.wikipedia.org/wiki/Denosumab: http://en.wikipedia.org/wiki/Denosumab
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.